This combination is indicated as an adjunct to diet and exercise as a once-daily therapy to improve glycaemic control in patients with type 2 diabetes mellitus. It is used in patients who are already receiving combined Pioglitazone and a sulfonylurea, or in those whose diabetes is not adequately controlled with sulfonylurea alone, or in patients who initially respond to Pioglitazone monotherapy but require additional glycaemic control.

Pioglitazone & Glimepiride is a combination of two antihyperglycaemic agents with different mechanisms of action used to improve glycaemic control in type 2 diabetes mellitus. It contains Pioglitazone (a thiazolidinedione) and Glimepiride (a sulfonylurea).

Pioglitazone is an insulin sensitizer that enhances peripheral glucose utilization. Its action depends on the presence of insulin. It reduces insulin resistance in peripheral tissues and the liver, resulting in increased insulin-dependent glucose uptake and decreased hepatic glucose production. It is a selective agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ), which regulates genes involved in glucose and lipid metabolism.

Glimepiride lowers blood glucose primarily by stimulating insulin secretion from functional pancreatic beta cells. It may also exert extrapancreatic effects by increasing peripheral tissue sensitivity to insulin, as supported by both clinical and preclinical studies.

Selecting the starting dose of Glimepiride & Pioglitazone should be based on the patient's current regimen of Pioglitazone and/or sulfonylurea. Those patients who may be more sensitive to antihyperglycemic drugs should be monitored carefully during dose adjustment. It is recommended that a single dose of Pioglitazone & Glimepiride be administered once daily with the first main meal.

Starting dose for patients currently on Glimepiride monotherapy: Based on the usual starting dose of Pioglitazone (15 mg or 30 mg daily), Pioglitazone & Glimepiride may be initiated at 30 mg/2 mg or 30 mg/4 mg tablet strengths once daily, and adjusted after assessing adequacy of therapeutic response.

Starting dose for patients currently on Pioglitazone monotherapy: Based on the usual starting doses of Glimepiride (1 mg or 2 mg once daily), and Pioglitazone 15 mg or 30 mg, Pioglitazone & Glimepiride may be initiated at 30 mg/2 mg once daily, and adjusted after assessing adequacy of therapeutic response.

Starting dose for patients switching from combination therapy of Pioglitazone plus Glimepiride as separate tablets: Pioglitazone & Glimepiride may be initiated with 30 mg/2 mg or 30 mg/4 mg tablet strengths based on the dose of Pioglitazone and Glimepiride already being taken. Patients who are not controlled with 15 mg of Pioglitazone in combination with Glimepiride should be carefully monitored when switched to Pioglitazone & Glimepiride.

Starting dose for patients currently on a different sulfonylurea monotherapy or switching from combination therapy of Pioglitazone plus a different sulfonylurea: No exact dosage relationship exists between Glimepiride and the other sulfonylurea agents. Therefore, based on the maximum starting dose of 2 mg Glimepiride, Pioglitazone & Glimepiride should be limited initially to a starting dose of 30 mg/2 mg once daily, and adjusted after assessing adequacy of therapeutic response.

Glimepiride: Certain drugs may increase blood glucose levels and lead to loss of glycaemic control. These include thiazide and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, and isoniazid. When these are used with glimepiride, patients should be closely monitored for loss of control. When such drugs are withdrawn, there is a risk of hypoglycaemia and close monitoring is required. A serious interaction between oral miconazole and oral hypoglycaemic agents may cause severe hypoglycaemia. Interactions may also occur with drugs metabolized by CYP2C9 such as phenytoin, diclofenac, ibuprofen, naproxen, and mefenamic acid.

Pioglitazone: Co-administration with oral contraceptives may reduce plasma concentrations of ethinyl estradiol. No significant changes were observed in norethindrone levels. Pioglitazone does not significantly affect the pharmacokinetics of fexofenadine, metformin, digoxin, warfarin, ranitidine, or theophylline.

The combination of Pioglitazone and Glimepiride is contraindicated in patients with known hypersensitivity to either drug or any component of the formulation. It is also contraindicated in diabetic ketoacidosis with or without coma, which should be treated with insulin.

Pioglitazone: Common adverse effects include upper respiratory tract infection, headache, sinusitis, myalgia, tooth disorder, pharyngitis, and edema. In combination therapy, similar adverse effects may occur.

Glimepiride: The most important adverse effect is hypoglycaemia. Other possible effects include dizziness, asthenia, headache, nausea, and rare allergic skin reactions such as itching, redness, urticaria, and rash, which may be temporary.

Pregnancy Category C. Current evidence strongly suggests that abnormal blood glucose levels during pregnancy are associated with an increased risk of congenital anomalies as well as higher neonatal morbidity and mortality. Therefore, most experts recommend insulin monotherapy during pregnancy to maintain near-normal blood glucose levels. The combination of Pioglitazone and Glimepiride should not be used during pregnancy.

Nursing mothers: No studies have been conducted on the combination of Pioglitazone and Glimepiride. It is not known whether Pioglitazone and/or Glimepiride are excreted in human breast milk. Since many drugs are excreted in breast milk, this combination should not be used in breastfeeding women.

General: Due to its mechanism of action, Pioglitazone is effective only in the presence of endogenous insulin. Therefore, this combination should not be used in type 1 diabetes or for diabetic ketoacidosis.

Hypoglycaemia: All sulfonylureas can cause severe hypoglycaemia. Proper patient selection, correct dosing, and clear instructions are essential. Elderly, debilitated, or malnourished patients, and those with adrenal, pituitary, renal, or hepatic insufficiency are at higher risk.

Loss of glycaemic control: During stress conditions such as fever, trauma, infection, or surgery, temporary loss of blood glucose control may occur. In such cases, the combination may need to be withheld and insulin may be temporarily required. Treatment can be restarted after recovery.

Edema: Pioglitazone may cause fluid retention and should be used with caution in patients with edema or at risk of heart failure, as it may worsen or precipitate congestive heart failure.

Weight gain: Dose-related weight gain may occur due to fluid retention and fat accumulation.

Hepatic effects: Liver function tests should be performed before starting therapy and periodically thereafter. Treatment should not be initiated if ALT is more than 2.5 times the upper limit of normal. If ALT exceeds 3 times the upper limit of normal during therapy, it should be rechecked promptly and treatment discontinued if levels remain elevated. Patients developing symptoms of liver dysfunction such as nausea, vomiting, abdominal pain, fatigue, anorexia, or dark urine should undergo liver function evaluation.

Pediatric Use: Safety and efficacy have not been established in children.

Geriatric Use: Pioglitazone does not require dose adjustment in elderly patients. Glimepiride should be used cautiously due to risk of hypoglycaemia, especially in those with reduced renal function, and renal monitoring is recommended.

Symptoms include severe hypoglycaemia with coma, seizures, or neurological impairment. Management includes IV glucose or glucagon administration. Additional carbohydrate intake may be required as hypoglycaemia may recur after initial recovery.

Combination oral hypoglycaemic preparations

Store in a cool, dry place. Protect from light and moisture. Keep out of reach of children.